Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 38

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 14, 2010; 16(38): 4823-4831
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823

Full Size Figure Download Figure

Figure 3 Kaplan-Meier survival curve showing the unfavourable progression-free survival of patients with high-grade tumor budding.

Citation: Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010; 16(38): 4823-4831
URL: https://www.wjgnet.com/1007-9327/full/v16/i38/4823.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i38.4823

Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010; 16(38): 4823-4831 [PMID: 20939111 DOI: 10.3748/wjg.v16.i38.4823]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.